Becton Dickinson & Co (BDX)

BDX (NYSE:Health Services)
pos +0.00
Today's Range: 117.96 - 118.65 | BDX Avg Daily Volume: 710,500
Last Update: 07/25/14 - 4:02 PM EDT
Volume: 0
YTD Performance: 7.13%
Open: $0.00
Previous Close: $118.49
52 Week Range: $96.73 - $120.66
Oustanding Shares: 193,204,013
Market Cap: 22,892,743,500
6-Month Chart
TheStreet Ratings Grade for BDX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 7 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.47 2.50 2.50 2.50
Latest Dividend: 0.54
Latest Dividend Yield: 1.84%
Dividend Ex-Date: 09/05/14
Price Earnings Ratio: 24.95
Price Earnings Comparisons:
BDX Sector Avg. S&P 500
24.95 24.70 28.93
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.16% 14.35% 36.65%
Revenue 4.50 0.09 0.03
Net Income 10.50 -0.21 -0.07
EPS 16.30 0.18 0.06
Earnings for BDX:
Revenue 8.05B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (09/14) FY (09/15)
Average Estimate $1.68 $1.67 $6.25 $6.82
Number of Analysts 12 11 15 15
High Estimate $1.71 $1.69 $6.29 $6.90
Low Estimate $1.66 $1.65 $6.23 $6.75
Prior Year $1.58 $1.58 $5.95 $6.25
Growth Rate (Year over Year) 6.22% 5.75% 5.05% 9.10%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
A wave of M&A in the health sector makes sense.
If you step out of the blinding spotlight, the truly rewarding buying opportunities become obvious.
Jan 21, 2014 | 8:14 AM EST
BSX was upgraded to Overweight, Piper Jaffray said. $18 price target. Company is in the second leg of a multi-year move. 
Jan 07, 2014 | 8:41 AM EST
BDX was upgraded to Neutral, Bank of America/Merrill Lynch said. $117 price target. Sales and earnings growth should stabilize.
Sep 18, 2013 | 7:55 AM EDT
BDX was upgraded from Neutral to Overweight, Piper Jaffray said. $117 price target. Microbiology market should drive earnings growth.&n...
Three charts forming around their 50-day moving average.
Outperformance by safe sectors often signals trouble, but not always.
Jan 29, 2013 | 6:19 AM EST
 BD Annual Shareholder Meeting - 1PM

Portfolio Mgr. David Peltier uncovers a low-dollar healthcare stock with big growth potential.

Grab Some for the Next Leg Up Real Money Pro($)

This high-quality name seems ready for another sizable climb.

Columnist Conversations

Index Chart of the Day: SPX and RUT Divergence SPX vs. RUT (YTD) View Chart »&nbs...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
The S&P 500 index finished the week unchanged, but the VIX was up 5%, the divergence sending a bit of a mi...
Weyerhaeuser has been struggling since testing the 2013 highs last month. The stock extended a powerful...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.